Jasper Therapeutics, Inc. (JSPR) financial statements and ratios from SEC XBRL: revenue $1.74M (TTM), net margin -4353.9%, revenue growth -81.2% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $1.74M |
| Net Margin | -4353.9% |
| Return on Equity | -2248.5% |
| Current Ratio | 1.47 |
| Revenue Growth (YoY) | -81.2% |
| EPS Growth (YoY) | -94.3% |
| EV / EBITDA | -0.3 |
| Price / Book | 18.60 |
| Price / Sales | 28.39 |
| FCF Yield | -229.5% |
| Altman Z-Score | -19.12 (distress) |
| Sector P/E (Healthcare) | 21.7 |
JSPR overview · JSPR earnings · JSPR KPIs · JSPR investor relations · JSPR ownership · JSPR peers · JSPR filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.